Policy & Regulation
Valneva reports positive Phase III results of COVID-19 vaccine candidate
18 October 2021 -

French biotechnology company Valneva SE (EPA:VLA) has reported positive Phase III results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001, Reuters news agency reported on Monday.

According to the company, its latest trial conducted on 4,012 participants aged 18 and older across 26 trial sites in Britain, showed the vaccine prompted a stronger immune response and fewer side-effects than AstraZeneca's (LON:AZN) shot.

Reportedly, Valneva is among a handful of vaccine developers testing their vaccines against one already approved by a regulator, rather than giving volunteers a placebo as shots become more available.

Valneva's Chief Executive, Thomas Lingelbach, was quoted as saying: "These results confirm the advantages often associated with inactivated whole virus vaccines," adding that the company believed it would make an important contribution to the fight against COVID-19.

Login
Username:

Password:


Related Headlines